NETs; HIF-1 and T cells immunology; antimicrobial resistance; tuberculosis vaccine (protein, DNA) immunologic mechanism; clostridium difficile and helicobacter pylori vaccine; SARS COVID-19 neutralizer antibodies
Contractile and Kinetic Properties of Failing Human Myocardium; Cardiovascular Dysfunctions and Complications Associated with Thyroid Gland Disorders; the Differences in Contractile Protein Expression across Different Age Groups in Human Myocardial Tissue
Vascular surgery; arteriovenous fistula; AVF; Artery; Vein; Varicose veins; AAA; Abdominal aortic aneurysms; carotid disease; endarterectomy; peripheral arterial disease; PAD; acute limb ischemia; critical limb ischemia; revascularization; revascularization of the lower limbs; Bioengineering; biomechanical properties; aneurysmal dilatation; vascular trauma; arterial reconstruction; by-pass; angioplasty; aneurysmal rupture; adventitial collagen; photochemical crosslinking; mechanical reinforcement; proteolytic resistance; designing therapeutic strategies.
aneurysms (abdominal, thoracic, peripheral); peripheral artery disease and chronic limb-threatening ischemia; supra aortic vessel disease; aortic dissection; venous disease; vascular medicine.
faecal immunochemical test; mass screening; screening programme; interval colorectal cancer; molecular characterization; fecal immunochemical test; screening program; temperature; humidity; colorectal cancer; microbiome; shotgun; metagenomics; MWAS; meta-analysis; predictive model; colorectal cancer screening; Colorectal cancer screening; Colorectal Cancer Screening; colon cancer; gut microbiota; 16S; microbial signature
The Dey lab is characterizing how the gut microbiota interfaces with the host to regulate physiology (e.g. gut motility) and pathophysiology (e.g. colorectal cancer), with an initial focus on how bile acids (and differential bacterial bile acid metabolism) mediate these effects.
epigenetic alterations based on DNA methylation and non-coding RNAs with clinical utility in cancer.
identification and clinical evaluation of new epigenetic biomarkers through the analysis of tumor samples and liquid biopsy to achieve precision oncology.
Dr. Marco Bregni specializes in Hematology and Oncology. He has been a post-doctoral fellow at the Dana Farber Cancer Institute. He has worked in stem cell transplantation in leading Italian institutions, and has contributed to advance the field in stem cell transplantation in solid tumors. He has been the Chairman of the Solid Tumor Working Party of the EBMT, and is the President of the Annual Meeting of the EBMT in 2014 in Milano. His interests are mainly in cell therapy and immunotherapy of solid tumors.
• Genetic diseases;
• Cancer genome;
• Nutritional therapy;
• Sarcopenia;
• Epigenome;
• Biomarkers;
• Gastrointestinal malignancies
alternative splicing; colorectal cancer; cell dissemination and metastasis; relapse; EZH2; G9A; histone methylation; epigenetics; chromatin; cancer; histone acetylation; DNA methylation; precision medicine; functional precision medicine; organoids; solid tumors; Colorectal Cancer; Colorectal cancer; cancer driver genes; oncogenes; tumour suppressor genes; protein variants; oncogenic isoforms; splicing molecular mechanisms; splicing factors
colorectal cancer; cell-free DNA; RAS mutations; solid biopsy; -; Colorectal cancer; Clinical Trial; Molecular Targeted Therapies; clinical trial; molecular targeted therapies; Colorectal Cancer; clinical Trial; cancer stem cell; Clinical trial; metastatic colorectal cancer; Metastatic Colorectal Cancer
Colorectal cancer; miRNA-mRNA interactions; MicroRNA expression profile; ACSL6; PRPS1; PRPS2; WNT signaling pathway; Hippo signaling pathway; Apelin signaling pathway; Ferroptosis; triple negative breast cancer; basal-like breast cancer; microRNA; epigenetic modulation; TNBC molecular classification; intrinsic molecular subtypes; breast cancer; colorectal carcinoma; cancer stem cells; miRNAs; regulatory network; signaling pathways; feedback loop; clear cell renal cell carcinoma; membranous-cytoplasmic EGFR; nuclear EGFR; SGLT1;
She has been engaged in pathological diagnosis for more than 20 years and has comprehensive and solid tumor pathological diagnosis skills, especially in the diagnosis of digestive tract tumors. He is mainly good at accurate diagnosis of digestive tract tumors and early colorectal cancer. He has presided over many research projects, focusing on the application of artificial intelligence in pathology, familial hereditary colorectal cancer, colorectal cancer precancerous lesions, and early cancer.
colorectal cancer molecular diagnosis projects.
sequencing reagents and HRM reagents for colorectal cancer molecular diagnosis
sequencing reagents for gastrointestinal stromal tumor molecular diagnosis
the mechanism of MSK1 gene affecting the prognosis of colorectal cancer
cancer; Nutrition; vitamins; colorectal cancer to investigate associations between the plasma metabolome and colorectal cancer risk and progression, ovarian cancer; cancer treatement
Cancer; proteomics; molecular biology; genetics; microbiome; plasmodium; biomedical sciences; Biological Engineering; human genetic diseases; meta-genomics; phylogeny of the malaria vector